Glaxosmithkline Long Term Debt to Equity Trend from 2010 to 2021

GSK -  USA Stock  

USD 40.10  0.60  1.52%

Glaxosmithkline Plc Long Term Debt to Equity is increasing with very volatile movements from year to year. Long Term Debt to Equity is estimated to finish at 2.32 this year. For the period between 2010 and 2021, Glaxosmithkline Plc, Long Term Debt to Equity quarterly trend regression had mean deviation of 1.96 and range of  11.52. Glaxosmithkline Plc Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 34.1 Billion. The current Selling General and Administrative Expense is estimated to increase to about 11.7 B, while Cost of Revenue is projected to decrease to under 11.5 B.

Search Historical Trends 

Check Glaxosmithkline Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Glaxosmithkline main balance sheet or income statement drivers, such as Direct Expenses of 10 B, Consolidated Income of 5.9 B or Cost of Revenue of 11.5 B, as well as many exotic indicators such as Interest Coverage of 7.51, Long Term Debt to Equity of 2.32 or Calculated Tax Rate of 8.59. Glaxosmithkline financial statements analysis is a perfect complement when working with Glaxosmithkline Plc Valuation or Volatility modules. It can also supplement various Glaxosmithkline Plc Technical models. Please check the analysis of Glaxosmithkline Plc Correlation against competitors.

Glaxosmithkline Long Term Debt to Equity Breakdown

Showing smoothed Long Term Debt to Equity of Glaxosmithkline Plc ADR with missing and latest data points interpolated. Glaxosmithkline Plc's Long Term Debt to Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Glaxosmithkline Plc's overall financial position and show how it may be relating to other accounts over time.
Long Term Debt to Equity10 Years Trend
Very volatile
 Long Term Debt to Equity 

Glaxosmithkline Long Term Debt to Equity Regression Statistics

Arithmetic Mean 3.57
Geometric Mean 2.87
Coefficient Of Variation 89.19
Mean Deviation 1.96
Median 2.53
Standard Deviation 3.18
Sample Variance 10.13
Range 11.52
R-Value 0.11
Mean Square Error 11.00
R-Squared 0.01287
Significance 0.73
Slope 0.10
Total Sum of Squares 111.40

Glaxosmithkline Long Term Debt to Equity History

2010  1.67 
2011  1.52 
2012  2.53 
2013  2.21 
2014  3.72 
2015  3.00 
2016  13.04 
2017  4.65 
2019  1.98 
2020  1.55 
2021  2.32 

About Glaxosmithkline Plc Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Glaxosmithkline Plc income statement, its balance sheet, and the statement of cash flows. Glaxosmithkline Plc investors use historical funamental indicators, such as Glaxosmithkline Plc's Long Term Debt to Equity, to determine how well the company is positioned to perform in the future. Although Glaxosmithkline Plc investors may use each financial statement separately, they are all related. The changes in Glaxosmithkline Plc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Glaxosmithkline Plc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Glaxosmithkline Plc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Glaxosmithkline Plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Long Term Debt to Equity 1.55  2.32 
Average Equity13.9 B15 B
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Glaxosmithkline Plc operates under Drug Manufacturers - General classification in the United States and is traded on New York Stock Exchange. It employs 94066 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Glaxosmithkline Plc without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now


Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Glaxosmithkline Plc ADR using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Glaxosmithkline Plc Correlation against competitors. Note that the Glaxosmithkline Plc ADR information on this page should be used as a complementary analysis to other Glaxosmithkline Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Glaxosmithkline Stock analysis

When running Glaxosmithkline Plc ADR price analysis, check to measure Glaxosmithkline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaxosmithkline Plc is operating at the current time. Most of Glaxosmithkline Plc's value examination focuses on studying past and present price action to predict the probability of Glaxosmithkline Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Glaxosmithkline Plc's price. Additionally, you may evaluate how the addition of Glaxosmithkline Plc to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Transaction History
View history of all your transactions and understand their impact on performance
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
The market value of Glaxosmithkline Plc ADR is measured differently than its book value, which is the value of Glaxosmithkline that is recorded on the company's balance sheet. Investors also form their own opinion of Glaxosmithkline Plc's value that differs from its market value or its book value, called intrinsic value, which is Glaxosmithkline Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Glaxosmithkline Plc's market value can be influenced by many factors that don't directly affect Glaxosmithkline Plc ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Glaxosmithkline Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Glaxosmithkline Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Glaxosmithkline Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.